Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)

11. november 2026 opdateret af: Han Chen, Fujian Provincial Hospital

A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring

Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.

Studieoversigt

Detaljeret beskrivelse

Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

100

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Fujian
      • Fuzhou, Fujian, Kina
        • Fujian Provincial Hospital
      • Fuzhou, Fujian, Kina
        • First Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, Kina
        • Hui'an County Hospital
      • Quanzhou, Fujian, Kina
        • Second Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, Kina
        • Shishi City Hospital
      • Zhangzhou, Fujian, Kina
        • Zhangzhou Municipal Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 90 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Continuous intracranial pressure monitoring for at least 24 hours
  • Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
  • Written informed consent from the patient or a legal representative

Exclusion Criteria:

  • Incomplete or unusable intracranial pressure recordings
  • Loss to follow-up or unavailable outcome information
  • Pre-existing severe neurological disease that would confound assessment

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Neurocritical care cohort

Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark.

Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Tidsramme: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval

24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Tidsramme: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals

48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Tidsramme: 24, 48 and 72 hours after intensive care admission

Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting.

24, 48 and 72 hours after intensive care admission
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Tidsramme: 24, 48 and 72 hours after intensive care admission

Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance.

24, 48 and 72 hours after intensive care admission
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Tidsramme: 24, 48 and 72 hours after intensive care admission

Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II

24, 48 and 72 hours after intensive care admission
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Tidsramme: 24 hours after intensive care admission

Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none

24 hours after intensive care admission
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Tidsramme: 24, 48 and 72 hours after intensive care admission

Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small

24, 48 and 72 hours after intensive care admission
28-day all-cause mortality, as specified in the approved protocol
Tidsramme: 28 days after intensive care admission
28 days after intensive care admission
Length of intensive care stay
Tidsramme: From intensive care admission to intensive care unit discharge, up to 28 days

Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care

From intensive care admission to intensive care unit discharge, up to 28 days
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Tidsramme: 6 months after intensive care admission

Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up

6 months after intensive care admission

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

12. december 2027

Studieafslutning (Anslået)

1. januar 2028

Datoer for studieregistrering

Først indsendt

7. november 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner